EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis - PubMed (original) (raw)

Practice Guideline

. 2018 Apr;73(4):765-798.

doi: 10.1111/all.13317. Epub 2017 Oct 30.

G Roberts 1 2 3, C A Akdis 6 7, I J Ansotegui 8, S R Durham 9, R Gerth van Wijk 10, S Halken 11, D Larenas-Linnemann 12, R Pawankar 13, C Pitsios 14, A Sheikh 15, M Worm 16, S Arasi 17 18, M A Calderon 9, C Cingi 19, S Dhami 20, J L Fauquert 21, E Hamelmann 22, P Hellings 23 24, L Jacobsen 25, E F Knol 26, S Y Lin 27, P Maggina 28, R Mösges 29, J N G Oude Elberink 30 31, G B Pajno 17, E A Pastorello 32, M Penagos 9, G Rotiroti 33, C B Schmidt-Weber 34, F Timmermans 35, O Tsilochristou 36, E-M Varga 37, J N Wilkinson 38, A Williams 39, L Zhang 40, I Agache 41, E Angier 42, M Fernandez-Rivas 43, M Jutel 44 45, S Lau 46, R van Ree 47, D Ryan 48, G J Sturm 49 50, A Muraro 51

Affiliations

Practice Guideline

EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

G Roberts et al. Allergy. 2018 Apr.

Abstract

Allergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project "EAACI Guidelines on Allergen Immunotherapy." It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children.

Keywords: allergen immunotherapy; allergic conjunctivitis; allergic rhinitis; allergy; rhinoconjunctivitis.

© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources